STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G/A

CRSP Schedule 13G/A filing by BlackRock

BlackRock reported beneficial ownership of 8.0M shares, representing 12% of CRISPR Therapeutics AG in this filing.

FiledJul 27, 2026
Ownership dateJun 30, 2026
Reported shares8.0M
Reported ownership12%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 7.8M
Shared voting power 8.0M
Sole dispositive power 8.0M
Shared dispositive power 8.0M
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$46.73as of Jul 27, 2026
Latest tracked price$52.45as of Aug 5, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
BlackRock
CIK
CIK0002012383
Accession
0002012383-26-002146
Form
Schedule 13G/A
Open SEC filing View CRSP ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →